Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $33.1600 (-0.24%) ($32.9500 - $33.1600) on Thu. Nov. 11, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.21% (three month average) | RSI | 63 | Latest Price | $33.1600(-0.24%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.9% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(62%) ARKK(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.605% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-6%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.605% (StdDev 3.21%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $34.28(-3.27%) | 10 Day Moving Average | $33.62(-1.37%) | 20 Day Moving Average | $32.82(1.04%) | To recent high | -6.8% | To recent low | 53% | Market Cap | $4.2b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |